Cellectis (CLLS)
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-ce...
- Open
- 3.325
- High
- 3.480
- Low
- 3.201
- Prev. Close
- 3.470
- Volume
- 26.66K
- Turnover
- 90.23K
- Avg Price
- 3.385
- Bid/Ask Ratio
- --
- Amplitude
- 8.04%
- 52wk High
- 5.480
- Volume Ratio
- 2.15
- Turnover Ratio
- 0.06%
Cellectis Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$7.60123.20%
Forecast & RatingBuy
5analysts
- Strong buy40.00%
- Buy40.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 19 at 01:40 AM
Cellectis (NASDAQ:CLLS) Shares Pass Above Fifty Day Moving Average - Here's Why
- prnewswire · Aug 12 at 09:31 AM
10:31 ETCAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
- PUBT · Aug 7 at 05:16 AM
Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform
- PUBT · Aug 6 at 04:58 PM
Cellectis expects interim readout in Q4 2026 from pivotal BALLI-01 trial of lasme-cel in relapsed/refractory B-cell ALL
- PUBT · Aug 6 at 03:33 PM
Cellectis H1 FY26 net loss narrows 5.49% to USD 39.58 million; revenue drops 52.19% to USD 14.45 million
- PUBT · Aug 5 at 03:38 PM
Cellectis reports 100,701,207 issued shares, 105,554,794 voting rights as of July 31, 2026
